Day: April 23, 2024

– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers Carlsbad, CA, April 23, 2024 (GLOBE NEWSWIRE) — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has entered into a transformative strategic collaboration with Strand Life Sciences, a leading bioinformatics specialist, aimed at advancing precision medicine for ulcerative colitis (UC) therapy. The collaboration with Strand Life Sciences provides Palisade...

WASHINGTON, April 23, 2024 (GLOBE NEWSWIRE) — As a featured sponsor, Verizon Frontline will demonstrate its suite of public safety solutions at Axon Week. Hosted by public safety technology leader Axon, Axon Week combines two conferences, Axon Accelerate and TASERCON, to assemble the best from public safety’s premier technology and training conferences. “Axon Week is the ideal environment to showcase Verizon Frontline’s public safety solutions,” said Michael Adams, vice president, public sector at Verizon. “When you talk to as many first responders as we do, you know right away that 5G is a top priority when it comes to doing their job safely, and efficiently,” Adams continued. “And through our 5G spectrum holdings, Verizon is able to more quickly expand and enhance our 5G Ultra Wideband network nationwide more than doubling and,...

VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, is thrilled to announce an innovative research and development partnership with the Kwantlen Polytechnic University Applied Genomics Centre (KPU-AGC). The project, entitled, “Genetic Identification of Psilocybin Containing Mushroom,” will utilize KPU-AGC’s state-of-the-art genomics technology to unravel the intricate genetic makeup of Optimi’s psilocybin-containing mushrooms, potentially paving the way for unprecedented advancements in the field of Psilocybin genetics. Optimi boasts an extensive genetic bank of over 200 psilocybin-containing mushroom strains, making it among the largest globally. The Company aims to produce mushrooms...

CAMARILLO, CA, April 23, 2024 (GLOBE NEWSWIRE) — Sacks Parente Golf, Inc. (Nasdaq: SPGC) (“SPG” or the “Company”), a technology-forward golf company with a growing portfolio of golf products, including putters, golf shafts, golf grips, and other golf-related accessories, announces that Executive Chairman Greg Campbell and Chief Financial Officer Steve Handy will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2024. The conference is being held on April 30 – May 2, 2024 at the Paris Hotel & Casino in Las Vegas.Presentation Date:  May 1, 2024   Time:  10:00am Pacific Time   Webcast Link: https://www.webcaster4.com/Webcast/Page/3026/50198   Mr. Campbell and Mr. Handy will be available for one-on-one meetings throughout the conference. Investors can attend the conference and request a meeting...

Continued progress against December 2023 Strategic Outlook, releases preliminary first quarter 2024 results, and announces first quarter financial results and conference call timing EDISON, N.J., April 23, 2024 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), a leading provider of safe, scalable, efficient, and sustainable zinc-based energy storage systems, today provided an update on the goals outlined in the December 2023 Strategic Outlook and its preliminary first quarter results. Eos continues to reach milestones necessary to achieve the goals outlined in the Strategic Outlook in December 2023, particularly related to cost reduction initiatives, Project AMAZE implementation and Eos Z3™ production. “The team continues to progress towards the milestones and goals presented during...

Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced positive data in the final validation report from the recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). The PK study was conducted as part of non-GLP small animal dose-ranging study of SPC-15 completed in February 2024. The activity of SPC-15 in the subjects or the PK study was evaluated over a 7-day repeat intranasal dose, including the processes of absorption, distribution,...

TORONTO and NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (“illumin” or the “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced the relaunch of illumin Elect with a direct, in platform integration to L2’s comprehensive voter database. This new integration dramatically reduces the turnaround time for building and utilizing custom audiences for political campaigns, revolutionizing the landscape of political campaign marketing. illumin Elect maximizes the capabilities of its existing connected journey advertising platform, facilitating efficient customization of political advertisements. Marketers gain access to integrated social media campaigns across Facebook and Instagram, enabling tailored...